ASSESSMENT OF CORTICOSTEROID (CS)-ASSOCIATED ADVERSE EVENTS (AES) WITH LONG-TERM (LT) EXPOSURE TO LOW-DOSE PREDNISONE (P) GIVEN WITH ABIRATERONE ACETATE (AA) TO METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS)

被引：1
|
作者：
Gomella, Leonard G.
Chi, Kim N.
de Bono, Johann S.
Fizazi, Karim
Miller, Kurt
Rathkopf, Dana E.
Ryan, Charles J.
Scher, Howard I.
Shore, Neal D.
De Porre, Peter
Londhe, Anil
McGowan, Tracy
Pelhivanov, Nonko
Charnas, Robert
Todd, Mary B.
Montgomery, Bruce
机构：
来源：
JOURNAL OF UROLOGY | 2015年 / 193卷 / 04期
关键词：
D O I：
10.1016/j.juro.2015.02.1963
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP87-18
引用
收藏
页码：E1091 / E1091
页数：1
相关论文
共 50 条
  • [31] Potential prognostic and predictive factors in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) in daily clinical practice in Spain.
    Celiz, Pamela
    Pinto, Alvaro
    Puente, Javier
    Manneh, Ray
    Gonzalez Larriba, Jose Luis
    Grande, Enrique
    Alonso, Teresa
    Manuel Sepulveda, Juan
    Rodriguez, Alfredo
    Castellano, Daniel E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors
    Verzoni, Elena
    Grassi, Paolo
    Ratta, Raffaele
    Niger, Monica
    De Braud, Filippo
    Valdagni, Riccardo
    Procopio, Giuseppe
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2016, 8 (05) : 323 - 330
  • [33] Does Gleason score (GS) predict efficacy of abiraterone acetate (AA) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)? An analysis of AA phase 3 trials
    Fizazi, Karim
    Flaig, Thomas W.
    Ohlmann, Carsten-Henning
    Scher, Howard I.
    De Bono, Johann Sebastian
    Rathkopf, Dana E.
    Ryan, Charles J.
    Kheoh, Thian San
    Li, Jinhui
    Todd, Mary Beth
    Griffin, Thomas W.
    Molina, Arturo
    Stoeckle, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [34] A hypothesis-generating exploratory analysis of efficacy and safety of abiraterone acetate (AA) in African American (Af Am) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Efstathiou, Eleni
    Assikis, Vasily J.
    North, Scott A.
    Showel, John
    Hutson, Thomas E.
    Riggs, Stephen Boyd
    Waxman, Jonathan
    Park, Youn Choi
    Kheoh, Thian San
    Haqq, Christopher M.
    Logothetis, Christopher
    Molina, Arturo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [35] Association between levels of hormones implied in steroid biosynthesis pathway and activity of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): an exploratory analysis
    Tucci, M.
    Bertaglia, V.
    Vignani, F.
    Buttigliero, C.
    Berruti, A.
    Scagliotti, G. V.
    Di Maio, M.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 61 - 61
  • [36] Prognostic index model (PIM) for overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy treated with abiraterone acetate (AA).
    Ryan, Charles J.
    Kheoh, Thian
    Li, Jinhui
    Molina, Arturo
    De Porre, Peter
    Carles, Joan
    Efstathiou, Eleni
    Kantoff, Philip W.
    Mulders, Peter F. A.
    Saad, Fred
    Griffin, Thomas W.
    Chi, Kim N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] EFFICACY AND LONG-TERM SAFETY ANALYSIS OF STUDY COU-AA-302: ABIRATERONE ACETATE PLUS PREDNISONE IN CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Shore, Neal
    Rathkopf, Dana
    Smith, Matthew R.
    de Bono, Johann S.
    Logothetis, Christopher
    de Souza, Paul
    Fizazi, Karim
    Mulders, Peter F. A.
    Mainwaring, Paul
    Hainsworth, John D.
    Beer, Tomasz M.
    North, Scott
    Fradet, Yves
    Griffin, Thomas
    Park, Youn C.
    Kheoh, Thian
    Small, Eric J.
    Scher, Howard I.
    Molina, Arturo
    Ryan, Charles J.
    [J]. JOURNAL OF UROLOGY, 2014, 191 (04): : E764 - E764
  • [38] HSD3B1 polymorphism in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP): Pharmacodynamics and therapeutic implications.
    Bastos, Diogo Assed
    Camargo, Anamaria Aranha
    Zylberberg, Ricardo
    Fontes Jardim, Denis Leonardo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [39] Re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035 Corticosteroid-associated Adverse Events in Elderly Patients
    Roviello, Giandomenico
    Bottini, Alberto
    Generali, Daniele
    [J]. EUROPEAN UROLOGY, 2016, 70 (02) : E41 - E41
  • [40] Weekly low-dose docetaxel is an effective treatment with fewer adverse events for metastatic castration-resistant prostate cancer in Taiwanese patients
    Kao, Cheng-Li
    Cha, Tai-Lung
    Kao, Chien-Chang
    Tsao, Chu-Wei
    Tang, Shou-Hung
    Meng, En
    Sun, Guang-Haun
    Yu, Dah-Shyong
    Chen, Bo-Han
    Wu, Sheng-Tang
    [J]. UROLOGICAL SCIENCE, 2015, 26 (04) : 267 - 270
12345